Polaryx Therapeutics (PLYX) Enterprise Value (2024 - 2026)
Polaryx Therapeutics (PLYX) posted quarterly Enterprise Value of -$3.1 million for Q1 2026, up 40.11% quarter-over-quarter from -$5.1 million in Q4 2025.
Polaryx Therapeutics (PLYX) Enterprise Value (2024 - 2026) Analysis & Trends
Polaryx Therapeutics (PLYX) has reported Enterprise Value for 3 consecutive years, with -$3.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value changed N/A year-over-year to -$3.1 million; the TTM figure through Mar 2026 stood at -$3.1 million (changed N/A YoY), while the FY2025 annual figure was -$5.1 million, down 11.3% from the prior year.
- Enterprise Value improved to -$3.1 million in Q1 2026 per PLYX's latest filing, from -$5.1 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$3.1 million in Q1 2026 and bottomed at -$5.1 million in Q4 2025.
- Historically, Enterprise Value has averaged -$4.3 million across 3 years, with a median of -$4.6 million in 2024.
- On a YoY basis, Enterprise Value climbed as much as 11.3% in 2025 and fell as far as 11.3% in 2025.
- Polaryx Therapeutics' Enterprise Value stood at -$4.6 million in 2024, then dropped by 11.3% to -$5.1 million in 2025, then soared by 40.11% to -$3.1 million in 2026.
- Business Quant data shows PLYX's Enterprise Value at -$3.1 million in Q1 2026, -$5.1 million in Q4 2025, and -$4.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Polaryx Therapeutics | 102.35 Mn | 90.81 Mn | - | -11.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.54 Mn |
| Mar 31, 2026 | -3.08 Mn |
| Dec 31, 2025 | -5.14 Mn |
| Dec 31, 2024 | -4.62 Mn |